Drug profile · INN
sulfacetamide sodium
KLARON
sulfacetamide sodium (KLARON) is a bacterial dihydropteroate synthase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — sulfacetamide sodium
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 17
- Programs
- 4
- Data quality
- 0.84
Quick answer
sulfacetamide sodium (KLARON) is a bacterial dihydropteroate synthase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 11802110
2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
US 11241415
N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor
granted -
US 10322107
N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor
granted -
US 8980887
2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof
granted -
US 7459458
Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
granted -
US 7410979
Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
granted -
US 7384623
High energy phototherapeutic agents
granted -
US 7353829
Methods and apparatus for multi-photon photo-activation of therapeutic agents
granted -
US 7348429
Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process
granted -
US 7304069
Hydrate of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5α]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto
granted -
US 6958342
Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
expired -
US 6903106
Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
expired -
US 6884888
Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
expired -
US 6544999
Polymorphs of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-&agr;]- pyrimidin-9-yl}phenyl)acetamide and compositions and methods related thereto
expired -
US 6384221
Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
expired
Frequently asked questions
What is sulfacetamide sodium?
sulfacetamide sodium (KLARON) is a bacterial dihydropteroate synthase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for sulfacetamide sodium?
KLARON is a marketed brand name for sulfacetamide sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfacetamide sodium?
sulfacetamide sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.